Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord-mesenchymal stem cells (UC-MSCs) are multipotent stromal cells derived from the Wharton's jelly or other tissues of the umbilical cord. These cells possess the ability to self-renew and differentiate into various mesodermal lineages, including bone, cartilage, and fat cells. UC-MSCs are characterized by their low immunogenicity and potent immunomodulatory properties, making them suitable for allogenic transplantation without the need for rigorous HLA matching. In the context of dental and periodontal medicine, UC-MSCs are being investigated for their regenerative potential to reconstruct deficient interdental papilla and treat gingival recession. The University of Malaya has conducted clinical research evaluating the efficacy of these cells when locally injected to promote tissue regeneration in the oral cavity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord-mesenchymal stem cells (044c43).